TC Home

The only technical publication dedicated to readers who formulate, manufacture, or package solid dosage forms.

Slide background
Slide background
  • February 23, 2020

PHILADELPHIA, PA—PCI Pharma Services, a pharmaceutical and biopharmaceutical CDMO, has announced an expansion of its Tredegar facility in Wales, UK, to strengthen its high-potency drug manufacturing and development capabilities including both clinical and commercial supply. The investment involves expanding the contained oral solid dosage form manufacturing facility to double the large-scale granulation and fluid-bed drying capacity. The expansion will also include additional space for new potent handling capabilities, additional analytical capacity, and a small-scale processing area to allow early stage non-GMP processing and formulation. The expansion is expected to be completed in late 2021.